keyword
MENU ▼
Read by QxMD icon Read
search

Avastin

keyword
https://www.readbyqxmd.com/read/28048647/tu-d-207b-07-radiomic-response-assessment-for-recurrent-glioblastoma-treated-with-bevacizumab-in-the-brain-trial
#1
P Grossmann, V Narayan, R Huang, H Aerts
PURPOSE: To develop radiomic biomarkers for non-invasive response assessment of Bevacizumab (Avastin; Genentech) treatment in recurrent glioblastoma multiforme (GBM). METHODS: We analyzed prospectively acquired data from the BRAIN trial. For 167 patients, we extracted 71 radiomic features each from normalized post-contrast T1-weighted and fluid attenuation inversion recovery (FLAIR) sequences at baseline (pretreatment), and at follow-ups of six and twelve weeks (post-treatment), respectively, where available...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28035003/a-quininib-analogue-and-cysteinyl-leukotreine-receptor-antagonist-inhibits-vegf-independent-angiogenesis-and-exerts-an-additive-anti-angiogenic-response-with-bevacizumab
#2
Clare T Butler, Alison L Reynolds, Miriam Tosetto, Eugene T Dillon, Patrick Guiry, Gerard Cagney, Jacintha O'Sullivan, Breand Aacuten N Kennedy
Excess blood vessel growth contributes to the pathology of metastatic cancers and age-related retinopathies. Despite development of improved treatments, these conditions are associated with high economic costs and drug resistance. Bevacizumab (Avastin®), a monoclonal antibody against vascular endothelial growth factor (VEGF) is used clinically to treat certain types of metastatic cancers. Unfortunately, many patients do not respond or inevitably become resistant to bevacizumab, highlighting the need for more effective anti-angiogenic drugs with novel mechanisms of action...
December 29, 2016: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/27999187/targeting-the-pro-angiogenic-forms-of-vegf-or-inhibiting-their-expression-as-anti-cancer-strategies
#3
Mélanie Guyot, Caroline Hilmi, Damien Ambrosetti, Marco Merlano, Cristiana Lo Nigro, Jérôme Durivault, Renaud Grépin, Gilles Pagès
Tumor growth relies on oxygen and blood supply depending on neo-vascularization. This process is mediated by the Vascular Endothelial Growth Factor (VEGF) in many tumors. This paradigm has led to the development of specific therapeutic approaches targeting VEGF or its receptors. Despite their promising effects, these strategies have not improved overall survival of patients suffering from different cancers compared to standard therapies. We hypothesized that the existence of anti-angiogenic forms of VEGF VEGFxxxb which are still present in many tumors limit the therapeutic effects of the anti-VEGF antibodies bevacizumab/Avastin (BVZ)...
December 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27996119/bevacizumab-chemotherapy-for-management-of-pulmonary-and-laryngotracheal-papillomatosis-in-a-child
#4
Karen B Zur, Elizabeth Fox
Recurrent laryngeal papillomatosis (RRP) can be a devastating condition for a child to endure, and pulmonary involvement may have terminal consequences. Adjuvant therapies have been trialed and reported over the years; however, these chemotherapy options have not been successful. Bevacizumab (Avastin, Genetech Inc., South San Francisco, CA) is a vascular endothelial factor (VEGF) inhibitor that has shown promise in the management of papillomatosis. Most research has focused on intralesional injections of this antiangiogenic drug...
December 20, 2016: Laryngoscope
https://www.readbyqxmd.com/read/27972449/a-budget-impact-analysis-to-estimate-the-economic-consequences-of-introducing-the-combination-of-avastin-tarceva-for-the-treatment-of-first-line-epidermal-growth-factor-egfr-metastatic-non-small-cell-lung-cancer-nsclc
#5
P Orfanos, E J Wright, V C Munk
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27930983/sargassum-fusiforme-polysaccharides-inhibit-vegf-a-related-angiogenesis-and-proliferation-of-lung-cancer-in-vitro-and-in-vivo
#6
Huiling Chen, Ling Zhang, Xiange Long, Peifei Li, Shengcan Chen, Wei Kuang, Junming Guo
Sargassum fusiforme (Harv.) is a brown alga belonging to the Sargasaceae family. The Sargassum fusiforme polysaccharides (SFPS) have demonstrated good anti-tumor and immunomodulatory activity. However, the underlying mechanisms of its anti-tumorigenesis, especially the anti-angiogenic activity is yet to be established. In the present study, we attempted to determine the effects of SFPS on the human lung adenocarcinoma SPC-A-1 cells and its xenograft model. The results showed that SFPS provides a concentration-dependent inhibition of SPC-A-1 cell proliferation in in vitro and the tumor growth in in vivo studies...
January 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27928444/the-remote-effects-of-intravitreal-anti-vegf-therapy
#7
Balta F, Merticariu M, Taban C, Neculau G, Merticariu A, Muresanu D, Badescu D, Jinga V
Objective: To study the effects of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) therapy with Avastin for wet Age-Related Macular Degeneration (AMD) on Benign Prostatic Hyperplasia (BPH)-related symptoms. Methods: An exploratory trial was conducted from August 1, 2013 to February 1, 2014, that included 14 male patients previously diagnosed with BPH, who were aged between 59 and 69 years. The trial was performed in Bucharest and involved two medical institutions: the Clinical Hospital of Eye Emergencies and the "Prof...
October 2016: Journal of Medicine and Life
https://www.readbyqxmd.com/read/27896177/anti-vascular-endothelial-growth-factor-bevacizumab-therapy-reduces-hypertrophic-scar-formation-in-a-rabbit-ear-wounding-model
#8
Do Hoon Kwak, Tae Hui Bae, Woo Seob Kim, Han Koo Kim
BACKGROUND: Hypertrophic scarring is a pathological condition that occurs after trauma or surgery. Angiogenesis occurs more often with hypertrophic scarring than with normotrophic scarring. The regulation of angiogenesis is one of the key factors in hypertrophic scar management. Vascular endothelial growth factor (VEGF) is an essential factor in the angiogenetic response. This study investigated whether decreasing the level of VEGF is effective for treating hypertrophic scarring. METHODS: Ten 8-week-old female New Zealand white rabbits were included...
November 2016: Archives of Plastic Surgery
https://www.readbyqxmd.com/read/27893676/combination-use-of-paclitaxel-and-avastin-enhances-treatment-effect-for-the-nsclc-patients-with-malignant-pleural-effusion
#9
Nan Qi, Fang Li, Xiaosong Li, Huanrong Kang, Hui Zhao, Nan Du
The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs).Twenty-four patients with non-small cell lung cancer were randomly assigned for 2 treatment approaches. Ten patients received paclitaxel (175 mg/m) alone, and 14 patients took a combination therapy of paclitaxel and Avastin (5 mg/kg). Efficacy of the treatment approaches in the patients was validated with the change in the MPE volume...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27882018/role-of-bevacizumab-in-the-prevention-of-early-postoperative-haemorrhage-after-25-gauge-microincision-vitrectomy-surgery
#10
Zaheer Sultan, Syed Fawad Rizvi, Faisal Murtaza Qureshi, Syed Asaad Mahmood
OBJECTIVE: To evaluate the effect of preoperative intravitreal bevacizumab injection on the incidence of postoperative haemorrhage and visual prognosis, in patients undergoing 25-gauge micro incision vitrectomy surgery (MIVS) for diabetic vitreous haemorrhage. METHODS: One hundred and twenty two eyes of 122 patients of diabetic retinopathy of both genders and aged over 18 years, who presented with non-resolving vitreous haemorrhage were enrolled for this study. All patients received an intravitreal injection of 1...
September 2016: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/27876365/midyear-commentary-on-trends-in-drug-delivery-and-clinical-translational-medicine-growth-in-biosimilar-complex-injectable-drug-formulation-products-within-evolving-collaborative-regulatory-interagency-fda-ftc-and-doj-practices-and-enforcement
#11
Rodney J Y Ho
Before the 2009 Biologics Price Competition and Innovation Act that enabled the U.S. Federal Drug Administration (FDA) to create the 351(k) Biologic License Application-an abbreviated biosimilar approval process, FDA approved follow-on biomolecule products such as beta-interferon, glucagon, hyaluronidase, and somatropin (human growth hormone) under varying and evolving rules. With the 351(k) Biologic License Application biosimilar approval process in place, currently, there are 4 (licensed in 2015-2016) biosimilars available, namely Neupogen (filgrastim; $1 B/y), Humira (adalumumab; $14...
February 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27824739/effect-of-the-lymphocyte-to-monocyte-ratio-on-the-clinical-outcome-of-chemotherapy-administration-in-advanced-melanoma-patients
#12
Alexey A Leontovich, Roxana S Dronca, Wendy K Nevala, Michael A Thompson, Lisa A Kottschade, Leonid V Ivanov, Svetomir N Markovic
Skin cancer affects more individuals in the USA than any other malignancy and malignant melanoma is particularly deadly because of its metastatic potential. Melanoma has been recognized as one of the most immunogenic malignancies; therefore, understanding the mechanisms of tumor-immune interaction is key for developing more efficient treatments. As the tumor microenvironment shows an immunosuppressive action, immunotherapeutic agents promoting endogenous immune response to cancer have been tested (interleukin-2, anticytotoxic-T-lymphocyte-associated antigen 4, and antiprogrammed cell death protein 1 monoclonal antibodies) as well as combinations of cytotoxic chemotherapy agents and inhibitors of angiogenesis (taxol/carboplatin/avastin)...
February 2017: Melanoma Research
https://www.readbyqxmd.com/read/27759858/the-effect-of-bevacizumab-pretreatment-on-the-choice-of-endotamponade-in-diabetic-tractional-retinal-detachment
#13
Mehmet Murat Uzel, Mehmet Citirik, Cagri Ilhan, Merve Inanc
BACKGROUND AND OBJECTIVE: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) injection on the choice of endotamponade at the end of surgery in patients who underwent pars plana vitrectomy (PPV) for diabetic tractional retinal detachment (DTRD). PATIENTS AND METHODS: Seventy-eight patients who had DTRD with macular involvement and underwent PPV by a single surgeon from January 2012 to May 2015 were included...
October 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27759856/optical-coherence-tomography-features-in-diabetic-macular-edema-and-the-impact-on-anti-vegf-response
#14
Yuji Itoh, Daniel Petkovsek, Peter K Kaiser, Rishi P Singh, Justis P Ehlers
BACKGROUND AND OBJECTIVE: To assess the relationship between spectral-domain optical coherence tomography (SD-OCT) features and functional outcomes for diabetic macular edema (DME) undergoing treatment with intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: Institutional review board-approved, retrospective, consecutive case series of eyes receiving intravitreal bevacizumab (1.25 mg) for DME. SD-OCT features were evaluated and correlated with functional response to anti-vascular endothelial growth factor (VEGF) therapy...
October 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27748633/the-safety-and-efficacy-of-bevacizumab-in-the-treatment-of-patients-with-recurrent-or-metastatic-cervical-cancer
#15
Lindsey E Minion, Krishnansu S Tewari
Introduction Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF) (Avastin; Genetech, Inc, San Francisco, CA). Angiogenesis is blocked by the binding of bevacizumab to VEGF, inhibiting the binding of this ligand to the VEGF receptor. On August 14, 2014 the Food and Drug Administration (FDA) approved use of bevacizumab in persistent, recurrent, or metastatic cervical cancer. Areas Covered Herein we review pharmacodynamics and kinetics, clinical data and treatment-related toxicities of bevacizumab in the treatment of metastatic, recurrent or persistent cervical cancer...
October 17, 2016: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/27631479/aflibercept-for-diabetic-macular-edema-in-eyes-previously-treated-with-ranibizumab-and-or-bevacizumab-may-further-improve-macular-thickness
#16
Chirag P Shah, Jeffrey S Heier
BACKGROUND AND OBJECTIVE: To evaluate the short-term anatomic and visual outcomes after aflibercept (Eylea; Regeneron, Tarrytown, NY) in eyes with diabetic macular edema (DME) previously treated with ranibizumab (Lucentis; Genentech, South San Francisco, CA) and/or bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A single-center, retrospective, noncomparative study of 30 eyes in 23 patients with DME treated with prior ranibizumab and/or bevacizumab before switching to aflibercept...
September 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27610261/a-rare-case-of-mixed-neuroendocrine-tumor-and-adenocarcinoma-of-the-pancreas
#17
Sofia Xenaki, Konstantinos Lasithiotakis, Alexandros Andreou, Sofia Aggelaki, Maria Tzardi, Anna Daskalaki, George Chalkiadakis, Emmanuel Chrysos
Introduction. Neuroendocrine carcinoma (NEC) of pancreas is a rare tumor with aggressive progression and poor prognosis. Its coexistence with adenocarcinoma poses significant clinical problems and has not been addressed in the literature. Methods. We describe a case of a 51-year-old male who underwent pancreatoduodenectomy due to pancreatic head tumor 1.5 × 1 × 1.4 cm. Histological examination of the specimen revealed a mixed neoplasm: (1) a well differentiated adenocarcinoma, neoplastic blasts of which are extended focally to the submucosa without invading the muscular layer, and (2) a low differentiated NEC consisting of solid clusters and pagetoid formations...
2016: Case Reports in Surgery
https://www.readbyqxmd.com/read/27591037/effect-of-treatment-of-rectal-cancer-metastasis-with-intravitreal-bevacizumab-avastin-in-patient-with-subretinal-fluid-and-macular-oedema-short-term-follow-up
#18
Joseph Daniel Boss, Philip Lieu, Asheesh Tewari
We describe the management of subretinal fluid and macular oedema due to colorectal cancer metastasis to the choroid using intravitreal bevacizumab. A patient with grade VI KRAS mutation rectal cancer with metastasis to the lung and cerebellum presented with left eye choroidal metastasis 1 week after being started on the experimental medication KTN3379. After intravitreal bevacizumab administration, the patient had improvement in macular subretinal fluid, but eventually progressed to severe cystoid macular oedema despite monthly intravitreal bevacizumab treatment...
September 2, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27555853/efficient-production-of-a-bioactive-bevacizumab-monoclonal-antibody-using-the-2a-self-cleavage-peptide-in-transgenic-rice-callus
#19
Lei Chen, Xiaoyu Yang, Da Luo, Weichang Yu
Bevacizumab, a humanized monoclonal antibody (mAb) targeting to the vascular endothelial growth factor (VEGF), has been widely used in clinical practice for the treatment of multiple cancers. Bevacizumab was mostly produced by the mammalian cell expression system. We here reported the first plant-derived Bevacizumab by using transgenic rice callus as an alternative gene expression system. Codon-optimized Bevacizumab light chain (BLC) and Bevacizumab heavy chain (BHC) genes were designed, synthesized as a polyprotein with a 2A self-cleavage linker peptide from the Foot-and-mouth disease virus, cloned into a plant binary vector under a constitutive maize ubiquitin promoter, and transformed into rice nuclear genome through Agrobacterium-mediated transformation...
2016: Frontiers in Plant Science
https://www.readbyqxmd.com/read/27499314/an-integrin-%C3%AE-v%C3%AE-3-antagonistic-modified-peptide-inhibits-tumor-growth-through-inhibition-of-the-erk-and-akt-signaling-pathways
#20
Lirong Hu, Jingjing Wang, Ying Wang, Hanmei Xu
HM-3, an RGD (Arg-Gly-Asp)-modified antitumor polypeptide designed independently, has been demonstrated for its robust inhibitory effects on tumors. However, the intravenous administration and short half-life in vivo are inconvenient to its clinical application. To solve these issues, PEGylated HM-3 (mPEG-SC20k-HM-3) with prolonged half‑time in vivo and subcutaneous administration was obtained after repeated screening of different types of PEG and numerous efficacy assays. The present study aimed to evaluate the antitumor activity and investigate the mechanism of the modified peptide to interpret the antitumor properties of mPEG-SC20k-HM-3 comprehensively and clearly...
October 2016: Oncology Reports
keyword
keyword
1771
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"